

Appln. No.: 10/565,040 US Filing Date: 1/18/2006

Case No.: 21423YP Page No.: 2

## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

1. (currently amended) A compound of formula I and pharmaceutically acceptable salts thereof:

$$R^{4b}$$
 $R^{4a}$ 
 $R^{7}$ 
 $R^{6a}$ 
 $R^{6a}$ 
 $R^{6c}$ 
 $R^{6c}$ 

wherein

R1 and R2 are independently selected from hydrogen and C1-4 alkyl;

R<sup>3a</sup> and R<sup>3b</sup> are independently selected from hydrogen and C<sub>1-4</sub> alkyl optionally substituted with 1 to 5 halogen atoms;

 $R^{4a}$  and  $R^{4b}$  are independently selected form hydrogen, halogen, and  $C_{1-4}$  alkyl optionally substituted with 1 to 4 groups selected from halogen,  $OR^a$ ,  $OC(O)R^a$ ,  $S(O)_kR^d$ ,  $OS(O)_2R^d$ , and  $NR^1R^2$ , or

 $R^{4a}$  and  $R^{4b}$  together with the carbon atom to which they are both attached form an exo-cyclic methylene optionally substituted with 1 to 2 groups selected from  $C_{1-4}$  alkyl optionally substituted with 1-5 halogens and  $C_{1-4}$  alkyloxy;

R<sup>5</sup> is selected from (1) C<sub>1-6</sub> alkyl optionally substituted with 1 to 5 groups independently selected from halogen, nitro, cyano, ORa, SRa, CORa, SO<sub>2</sub>Rd, CO<sub>2</sub>Ra, OC(O)Ra, NRbCc, NRbC(O)Ra, NRbC(O)<sub>2</sub>Ra, C(O)NRbRc, C<sub>3-8</sub> cycloalkyl, (2) C<sub>3-8</sub> cycloalkyl optionally

Appln. No.: 10/565,040 US Filing Date: 1/18/2006 Case No.: 21423YP

Page No.: 3

substituted with 1 to 5 groups independently selected from halogen, nitro, cyano and phenyl, (3) C<sub>3-6</sub> alkynyl, (4) C<sub>2-6</sub> alkenyl optionally substituted with hydroxyethyl, (5) (CH<sub>2</sub>)<sub>k</sub>-aryl optionally substituted with 1 to 3 groups independently selected from halogen, nitro, cyano, ORa, SRa, C(O)<sub>2</sub>Ra, C<sub>1-4</sub> alkyl and C<sub>1-3</sub> haloalkyl; (6) (CH<sub>2</sub>)<sub>k</sub>-heterocycle optionally substituted with 1 to 3 groups independently selected from halogen, nitro, cyano, ORa, SRa, C<sub>1-4</sub> alkyl and C<sub>1-3</sub> haloalkyl wherein said heterocycle is selected from (a) a 5-membered heteroaromatic ring having a ring heteroatom selected from N, O and S, and optionally having up to 3 additional ring nitrogen atoms wherein said ring is optionally benzo-fused; (b) a 6-membered heteroaromatic ring containing from 1 to 3 ring nitrogen atoms and N-oxides thereof, wherein said ring is optionally benzo-fused; and (c) a 5- or 6-membered non-aromatic heterocyclic ring selected from tetrahydrofuranyl, 5-oxotetrahydrofuranyl, 2-oxo-2H-pyranyl, 6-oxo-1,6-dihydropyridazinyl, (7) C(O)<sub>2</sub>Ra, and (8) C(O)NR<sup>b</sup>Rc;

R6a is selected from (1)—OSO<sub>2</sub>R<sup>8</sup>, (2)—NR<sup>8a</sup>SO<sub>2</sub>R<sup>9</sup>, and (3)—C(R<sup>8b</sup>)(R<sup>8e</sup>)SO<sub>2</sub>R<sup>9</sup>; R6b, R6c, and R6d are independently selected from (1) hydrogen, (2) halogen, (3) OSO<sub>2</sub>R<sup>8</sup>, (4) C<sub>1-4</sub> alkyl optionally substituted with 1 to 5 halogen atoms, (5) cyano, (6) nitro, (7) OR<sup>a</sup>, and (8) CO<sub>2</sub>R<sup>a</sup>, or

when attached to adjacent carbon atoms R<sup>6c</sup> and R<sup>6d</sup> together with the carbon atoms to which they are attached form a 5- to 8-membered saturated or unsaturated ring; R<sup>7</sup> is selected from (1) hydrogen, (2) halogen, (3) cyano, (4) nitro, (5) ORa, (6) CO<sub>2</sub>Ra, (7) C(O)NR<sup>b</sup>R<sup>c</sup>, and (8) C<sub>1-4</sub> alkyl optionally substituted with 1 to 5 halogen atoms, R<sup>8</sup> is selected from (1) C<sub>1-4</sub> alkyl optionally substituted with 1 to 5 halogen atoms, (2) (CH<sub>2</sub>)k-aryl optionally substituted with 1 to 3 groups independently selected from halogen, nitro, cyano, NRaC(O)Ra, ORa, SRa, CO<sub>2</sub>Ra, C<sub>1-4</sub> alkyl, C<sub>1-3</sub> haloalkyl and NR<sup>b</sup>R<sup>c</sup>, (3) NR<sup>b</sup>R<sup>c</sup>, and (4) hydrogen;

R8a is selected from hydrogen, C<sub>1</sub> 4 alkyl optionally substituted with 1 to 5 halogen atoms, halogen, and CO<sub>2</sub>Ra, or

when R<sup>6a</sup> and R<sup>6b</sup> are attached to adjacent atoms, R<sup>8a</sup> and R<sup>6b</sup> together complete 5- or 6-membered ring;

R8b and R8c are independently selected from hydrogen, C1\_4 alkyl optionally substituted with 1 to 5 halogen atoms, halogen, cyano, nitro, CO2Ra, and ORa;

Appln. No.: 10/565,040 US Filing Date: 1/18/2006 Case No.: 21423YP

Page No.: 4

R<sup>9</sup>-is-selected from (1) C<sub>1</sub>-4-alkyl optionally substituted with 1 to 5 halogen atoms, (2) aryl optionally substituted with 1 to 3 groups independently selected from halogen, nitro, cyano, NR<sup>a</sup>C(O)R<sup>a</sup>, OR<sup>a</sup>, SR<sup>a</sup>, CO<sub>2</sub>R<sup>a</sup>, C<sub>1</sub>-4-alkyl and C<sub>1</sub>-3 haloalkyl, and (3) (CH<sub>2</sub>)<sub>k</sub>-aryl optionally substituted with 1 to 3 groups independently selected from halogen, nitro, cyano, NR<sup>a</sup>C(O)R<sup>a</sup>, OR<sup>a</sup>, SR<sup>a</sup>, C(O)<sub>2</sub>R<sup>a</sup>, C<sub>1</sub>-4-alkyl and C<sub>1</sub>-3 haloalkyl, or

R8a and R9 together with the atoms to which they are attached form a 5- to 8-membered heterocyclic ring;

Ra, Rb and Rc are independently selected from (1) hydrogen, (2) C<sub>1-4</sub> alkyl optionally substituted with 1 to 5 halogen atoms, (3) phenyl optionally substituted with 1 to 3 groups selected from halogen, cyano, nitro, OH, C<sub>1-4</sub> alkyloxy, C<sub>3-6</sub> cycloalkyl and C<sub>1-4</sub> alkyl optionally substituted with 1 to 5 halogen atoms, and (4) C<sub>3-6</sub> cycloalkyl, or Rb and Rc together with the nitrogen atom to which they are attached form a 4-, 5-, or 6-membered ring optionally containing an additional heteroatom selected from N, O, and S; or Rb and Rc together with the nitrogen atom to which they are attached form a cyclic imide; Rd is selected from (1) C<sub>1-4</sub> alkyl optionally substituted with 1 to 5 halogen atoms, (2) C<sub>1-4</sub>

alkyloxy, (3) phenyl optionally substituted with 1 to 3 groups selected from halogen, cyano, nitro, OH, C<sub>1-4</sub> alkyloxy, C<sub>3-6</sub> cycloalkyl and C<sub>1-4</sub> alkyl optionally substituted with 1 to 5 halogen atoms, and (4) hydrogen;

X is selected from CH and N; Y is selected from C and S=O; and k is selected from 0, 1, and 2.

- 2. (original) A compound of Claim 1 wherein R<sup>5</sup> is selected from pyrimidinyl and C<sub>1-6</sub> alkyl optionally substituted with 1 to 5 groups independently selected from halogen.
  - 3. (original) A compound of Claim 1 wherein Y is C.
- 4. (currently amended) A compound of Claim 1 wherein R<sup>6a</sup> is OSO<sub>2</sub>R<sup>8</sup> and R<sup>8</sup> is selected from 2,2,2,-trifluoroethyl, trifluoromethyl, methyl, ethyl, propyl, isopropyl, phenyl, benzyl, and dimethylamino; or R<sup>6a</sup> is NHSO<sub>2</sub>R<sup>9</sup> and R<sup>9</sup> is methyl or trifluoromethyl.

Appln. No.: 10/565,040 US Filing Date: 1/18/2006

Case No.: 21423YP

Page No.: 5

(4

5. (original) A compound of Claim 1 wherein R6b is selected from hydrogen, fluorine, and chlorine.

6. (original) A compound of Claim 1 having the formula I(2):

$$R^{5}$$
 $R^{7}$ 
 $R^{6a}$ 
 $R^{6a}$ 
 $R^{6b}$ 
 $R^{6c}$ 

wherein X is N or CH, R<sup>3a</sup> is H or C<sub>1-4</sub>alkyl, R<sup>7</sup> is hydrogen or halogen, and R<sup>5</sup>, R<sup>6a</sup>, R<sup>6b</sup> and R<sup>6c</sup> have the same definitions as provided in Claim 1.

## 7. (canceled)

- 8. (currently amended) A compound of Claim 10-6 wherein R<sup>6</sup>a is OSO<sub>2</sub>R<sup>8</sup>; R<sup>8</sup> is selected from methyl, trifluoromethyl, ethyl, propyl, isopropyl, benzyl, dimethylamino, 2,2,2-trifluoroethyl, and phenyl; R<sup>6</sup>b is hydrogen or halogen, and R<sup>6</sup>c is hydrogen or halogen.
- 9. (currently amended) A compound of Claim 10-6 wherein R5 is pyrimidinyl or C1-4alkyl optionally substituted with 1 to 5 groups independently selected from halogen.
  - 10. (original) A compound selected from
- 3,3'-difluoro-4'-{[({1-[(pyrimidin-5-ylcarbonyl)amino]cyclopropyl}carbonyl)amino]methyl}-
- 1,1'-biphenyl-2-yl trifluoromethanesulfonate,
- 3,3'-difluoro-4'-{(1R)-1-[({1-[(trifluoroacetyl)amino]cyclopropyl}carbonyl)amino]ethyl}-1,1'-biphenyl-2-yl trifluoromethanesulfonate,

Appln. No.: 10/565,040 US Filing Date: 1/18/2006

Case No.: 21423YP Page No.: 6

- 3,3'-difluoro-4'-((1R)-1-{[(1-{[(trifluoromethyl)sulfonyl]amino}cyclopropyl)carbonyl]amino}-ethyl)-1,1'-biphenyl-2-yl trifluoromethanesulfonate,
- 1-({[(1R)-1-(3,3'-difluoro-2'-{[(trifluoromethyl)sulfonyl]oxy}-1,1'-biphenyl-4-yl)ethyl]amino}-carbonyl)cyclopropanaminium trifluoroacetate,
- 3,3'-difluoro-4'-{(1R)-1-[({1-[(trifluoroacetyl)amino]cyclopropyl}carbonyl)amino]ethyl}-1,1'-biphenyl-2-yl methanesulfonate,
- 5-chloro-3,3'-difluoro-4'-{(1R)-1-[({1-[(trifluoroacetyl)amino]cyclopropyl}carbonyl)amino]ethyl}-1,1'-biphenyl-2-yl trifluoromethanesulfonate,
- 3,3'-difluoro-4'-{(1R)-1-[({1-[(trifluoroacetyl)amino]cyclopropyl}carbonyl)amino]ethyl}-1,1'-biphenyl-2-yl ethanesulfonate,
- 3,3'-difluoro-4'-{(1R)-1-[({1-[(trifluoroacetyl)amino]cyclopropyl}carbonyl)amino]ethyl}-1,1'-biphenyl-2-yl propane-1-sulfonate
- 3,3'-difluoro-4'-{(1R)-1-[({1-[(trifluoroacetyl)amino]cyclopropyl}carbonyl)amino]ethyl}-1,1'-biphenyl-2-yl propane-2-sulfonate,
- 3,3'-difluoro-4'-{(1R)-1-[({1-[(trifluoroacetyl)amino]cyclopropyl}carbonyl)amino]ethyl}-1,1'-biphenyl-2-yl benzenesulfonate,
- $3,3'-difluoro-4'-\{(1R)-1-[(\{1-[(trifluoroacetyl)amino]cyclopropyl\}carbonyl)amino]ethyl\}-1,1'-biphenyl-2-yl phenylmethanesulfonate$
- 3,3'-difluoro-4'-{(1R)-1-[({1-[(trifluoroacetyl)amino]cyclopropyl}carbonyl)amino]ethyl}-1,1'-biphenyl-2-yl dimethylsulfamate,
- 3,3'-difluoro-4'-{(1R)-1-[({1-[(trifluoroacetyl)amino]cyclopropyl}carbonyl)amino]ethyl}-1,1'-biphenyl-2-yl 2,2,2-trifluoroethanesulfonate,
- 3-chloro-3'-fluoro-4'-{(1R)-1-[({1-[(trifluoroacetyl)amino]cyclopropyl}carbonyl)amino]ethyl}-1,1'-biphenyl-2-yl trifluoromethanesulfonate,
- 3'-fluoro-4'-{(1R)-1-[({1-[(trifluoroacetyl)amino]cyclopropyl}carbonyl)amino]ethyl}-2-{[(trifluoromethyl)sulfonyl]oxy}-1,1'-biphenyl-3-yl trifluoromethanesulfonate,
- N-(1-{[((1R)-1-{3,3'-difluoro-2'-[methyl(methylsulfonyl)amino]-1,1'-biphenyl-4-yl}ethyl)-amino]carbonyl}cyclopropyl)pyrimidine-5-carboxamide,
- N-(1-{[({3,3'-difluoro-2'-[(methylsulfonyl)amino]-1,1'-biphenyl-4-yl}methyl)amino]carbonyl}-cyclopropyl)pyrimidine-5-carboxamide,

Appln. No.: 10/565,040 'US Filing Date: 1/18/2006

> Case No.: 21423YP Page No.: 7

N-{1-[({[2'-(1,1-dioxido-1,2-thiazinan-2-yl)-3,3'-difluoro-1,1'-biphenyl-4-yl]methyl}amino)-carbonyl]cyclopropyl}pyrimidine-5-carboxamide,

N-[(1R)-1-(3,3'-difluoro-2'-{[(trifluoromethyl)sulfonyl]methyl}-1,1'-biphenyl-4-yl)ethyl]-1-[(trifluoroacetyl)amino]cyclopropanecarboxamide,

 $N-[(1R)-1-(3,3'-difluoro-2'-\{[(trifluoromethyl)sulfonyl]amino\}-1,1'-biphenyl-4-yl)ethyl]-1-[(trifluoroacetyl)amino]cyclopropanecarboxamide, and$ 

N-(1-{[((1R)-1-{3,3'-difluoro-2'-[(methylsulfonyl)amino]-1,1'-biphenyl-4-yl}ethyl)amino]-carbonyl}cyclopropyl)pyrimidine-5-carboxamide.

11. (original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 and a pharmaceutically acceptable carrier.

12 - 13 (canceled)

14. (new) The compound N-[(1R)-1-(2-fluoro-4-{1-[(trifluoromethyl)sulfonyl]-1,2,3,4-tetrahydroquinolin-8-yl}phenyl)ethyl]-1-[(trifluoroacetyl)amino]cyclopropane-carboxamide.